Clinical Trials · NCT07382024
Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation
- Phase
- N/A
- Recruitment status
- Not Yet Recruiting
- Sponsor
- National Taiwan University Hospital
- Enrollment
- 200
- Start date
- Jun 2026
- Locations
- 1 site, Taiwan
- Primary endpoint
- Atrial fibrillation burden at 3 months after catheter ablation